Skip to content

Educational reference only. Not medical advice, diagnosis, or treatment, and not dosing, injection, or purchasing guidance.Medical disclaimer

PCAC meeting, 23–24 July 2026

Figures below are from the FDA advisory-committee calendar page for the 23–24 July 2026 meeting, as updated on that page through 14 July 2026.

  • The meeting is the Pharmacy Compounding Advisory Committee. FDA says advisory committees give non-binding recommendations. FDA generally follows them but is not required to.
  • On 23 July 2026 the agenda is the 503A bulks list for BPC-157 (free base and acetate; use evaluated: ulcerative colitis), KPV (free base and acetate; wound healing and inflammatory conditions), TB-500 (free base and acetate; wound healing), and MOTs-C / MOTS-c (free base and acetate; obesity and osteoporosis).
  • On 24 July 2026 the agenda is emideltide / DSIP (free base and acetate; opioid withdrawal, chronic insomnia, and narcolepsy), semax (free base and acetate; cerebral ischemia, migraine, and trigeminal neuralgia), and epitalon (free base and acetate; insomnia).
  • The public docket printed on the page is FDA-2025-N-6895. The page says the docket closed on 22 July 2026.
  • The calendar page lists briefing documents, questions, a final agenda, a roster, and FDA presentations. This wiki does not extract a vote tally or FDA’s final listing decision from those files.

A proposal inside a briefing PDF is not reported here, because that PDF was not the source opened for the sentences above.

This page does not give doses, titration schedules, injection or implantation technique, preparation steps, or places to purchase a product.

Page record

  • Type: Regulation
  • Domain: peptides
  • Evidence: Not rated
  • Status: reviewed
  • Last reviewed: 2026-11-20

Regulatory status: U.S. FDA Pharmacy Compounding Advisory Committee, 23–24 July 2026. Recommendations are non-binding. Vote not extracted.

Sources

Referenced by

A link from another wiki page is not evidence. Facts should point at the sources above.